DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1970)

Human Immunodeficiency Virus | Epidemiology | Europe Data

Human Immunodeficiency Virus | Epidemiology | Europe Data

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

DRG Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and total prevalence of HIV for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s HIV therapy forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with HIV per year?
  • How will improvements in survival change the number of people living with HIV?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HIV over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following HIV patient populations:

  • Diagnosed incident cases
  • Total prevalent cases
  • Total prevalent cases by diagnosis
  • Diagnosed prevalent cases by treatment (mature pharmaceutical markets only)

Note: Coverage may vary by country and region.

Table of contents

  • Europe Data
    • Introduction
      • Diagnosed Incidence of HIV Infection per 100,000 People of All Ages per Year in 2017 and 2027
      • Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of HIV Infection over the Ten-Year Forecast Period
      • Number of Additional Incident Cases of HIV Infection Incurred over 2017-2027 in the Countries Under Study
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases
      • Total Prevalent Cases
      • Diagnosed Prevalent Cases
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: June 2017
  • Author(s): Sunali D. Goonesekera, SM
  • Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

Purchase Report

Recent reports:
You may also be interested in: